Retatrutide vs Semaglutide: Triple Agonist vs GLP-1

What is the difference between retatrutide and semaglutide?

The core difference is receptor count and approval status: retatrutide activates three hormone receptors and is investigational, while semaglutide activates one and is approved.

Semaglutide is a GLP-1 receptor agonist, a single-target molecule that copies the gut hormone GLP-1 (Wilding et al., NEJM 2021; doi:10.1056/NEJMoa2032183). It is approved by the FDA for chronic weight management under the brand Wegovy and for type 2 diabetes as Ozempic. Retatrutide, development name LY3437943, is a single peptide engineered to activate three receptors at once: GLP-1, GIP, and glucagon (Coskun et al., Cell Metabolism 2022, PMID 35985340). It is investigational. As of 2026 no regulator has approved it, and outside a clinical trial it is a research compound, not a medicine. So the comparison is not just one hormone target versus three. It is also a mature, approved drug versus an earlier-stage one whose strongest published data come from a smaller phase 2 trial.

Retatrutide vs semaglutide: the decision table

At a glance, retatrutide reported larger mean weight change in its trial, while semaglutide has the deeper evidence base and regulatory approval behind it.

The rows above are drawn from separate trials. The weight-change row in particular is a cross-trial read: the two numbers were measured in different studies over different time frames, so the table lines them up for reference, it does not report a contest between them.

How does each one work?

Both act on the GLP-1 pathway, but retatrutide adds two more receptor arms that semaglutide does not touch.

Semaglutide's single mechanism is GLP-1 receptor activation. That slows how fast the stomach empties, acts on brain appetite centers so meals feel smaller, and improves glucose handling (Wilding et al., NEJM 2021). It is the mechanism that opened the modern weight-loss drug class. Retatrutide keeps that GLP-1 arm and layers on two more (Coskun et al., Cell Metabolism 2022, PMID 35985340). The GIP receptor arm, shared with tirzepatide, is thought to add to the appetite and metabolic effect. The glucagon receptor arm is the part that is unique here: glucagon signaling can raise energy expenditure and push fat use in the liver, so the design idea was to cut food intake while also nudging the body to spend and mobilize more energy. More receptor targets is the leading explanation researchers give for why retatrutide's trial numbers ran higher than a single-target drug's, though hitting more receptors can also broaden the side-effect and monitoring picture. Both molecules use a fatty acid chain that binds to albumin in the blood, which slows clearance and is why each is dosed once a week (Coskun et al., Cell Metabolism 2022; Wegovy FDA label).

Retatrutide vs semaglutide for weight loss: what did the trials report?

In their separate trials, retatrutide reported a larger mean weight change than semaglutide, but the studies were not the same length or the same phase, so this is a cross-trial comparison.

Retatrutide's number comes from a phase 2 obesity trial (Jastreboff et al., NEJM 2023;389(6):514-526; doi:10.1056/NEJMoa2301972; PMID 37366315). It enrolled 338 adults with obesity, ran 48 weeks, and tested doses from 1 mg to 12 mg once weekly against placebo. The least squares mean weight change at 48 weeks reached about -24.2% at the 12 mg dose versus about -2.1% on placebo. At 24 weeks the 12 mg group was already at about -17.5%, and about 83% of that group lost at least 15% of body weight.

Semaglutide's number comes from STEP 1 (Wilding et al., NEJM 2021;384:989-1002; doi:10.1056/NEJMoa2032183; PMID 33567185), a phase 3 trial in 1,961 adults with overweight or obesity. Mean weight change was -15.3 kg versus -2.6 kg on placebo at week 68, and 50.5% of the semaglutide group reached at least a 15% loss.

Here is the honest read on the gap. Retatrutide's roughly 24% was reached in 48 weeks in a smaller phase 2 trial; semaglutide's roughly 15% was reached in 68 weeks in a much larger phase 3 trial. One reports a percentage of body weight, the other reports kilograms, and the doses, populations, and durations differ. The two results simply were not generated in the same study, so the difference is suggestive of retatrutide's potency but is not head-to-head proof. The trial that would settle it directly has not been published.

Which has stronger evidence, retatrutide or semaglutide?

Semaglutide has the deeper and more mature evidence base, including large phase 3 trials, regulatory approval, and a cardiovascular outcome trial. Retatrutide's strongest published data are still phase 2.

Semaglutide has been through multiple large phase 3 trials and is FDA-approved for both weight management and type 2 diabetes. It also has a dedicated cardiovascular outcome trial: SELECT (Lincoff et al., NEJM 2023;389(24):2221-2232; doi:10.1056/NEJMoa2307563; PMID 37952131) enrolled 17,604 adults with overweight or obesity and established cardiovascular disease but without diabetes, and reported that semaglutide cut major adverse cardiovascular events by about 20% (a primary event in 6.5% of the semaglutide group versus 8.0% of the placebo group, hazard ratio 0.80) over a mean follow-up of about 40 months. That kind of hard-outcome data does not yet exist for retatrutide. Retatrutide's headline weight figure is from a single phase 2 trial, with a large phase 3 program still running. So on evidence maturity, the scoreboard favors semaglutide clearly, even though retatrutide's early weight numbers are larger.

How do the side effects compare?

Both compounds report a similar side-effect signature dominated by gastrointestinal effects, worse during dose escalation, though retatrutide adds glucagon-related monitoring.

For both drugs the most common reported adverse events are gastrointestinal: nausea, diarrhea, vomiting, and constipation, mostly mild to moderate and most noticeable while the dose is being raised (Wilding et al., NEJM 2021; Jastreboff et al., NEJM 2023). In the semaglutide obesity trials these GI effects were the leading adverse events, and starting low and titrating slowly is the standard way trials reduced them. In retatrutide's phase 2 trial the same GI pattern held, adverse events led to stopping the drug in about 6% to 16% of participants (versus none on placebo), and the trial also reported dose-dependent increases in heart rate that peaked around 24 weeks and then declined (Jastreboff et al., NEJM 2023). Retatrutide's glucagon arm is a reason its trials watched blood sugar and heart rate closely; glucose control generally improved in the obesity trial, but glucagon signaling is why researchers monitor metabolic markers. These are findings measured in selected trial participants under supervision. They are not a safety guarantee, and both compounds carry warnings that a clinician assesses. Long-term safety across a general population is exactly what the ongoing retatrutide phase 3 program is built to test.

What dosing did the retatrutide and semaglutide trials report?

The ranges below reflect what published studies and commonly studied research protocols report. This is educational, not a prescription or a personal recommendation.

Both were studied with once-weekly subcutaneous injection and a slow step-up in dose over months, because starting low reduces stomach side effects. The table lists the doses each pivotal trial actually used, with the source for each.

One number is not "smaller" in a meaningful way here. Semaglutide's approved 2.4 mg weekly and retatrutide's 12 mg weekly are different molecules with different potency per milligram, so the milligram figures are not directly comparable. Retatrutide has no approved dose because it is not approved. Milligram-to-unit conversions on an insulin syringe have no fixed relationship to a reported dose; they depend entirely on the concentration a compound is reconstituted to, which is a labeling and handling detail managed under professional supervision. This page does not provide that arithmetic.

What are the half-lives?

Both are long-acting and dosed once weekly. Retatrutide's half-life is about 6 days; semaglutide's is about 1 week.

Retatrutide's phase 1b multiple-ascending-dose study reported a half-life of about 6 days, which is what supports once-weekly dosing (Urva et al., Lancet 2022; doi:10.1016/S0140-6736(22)02033-5). Semaglutide's elimination half-life is about 1 week, and it is more than 99% bound to plasma albumin, which slows clearance (Wegovy FDA prescribing information). Both use the same design trick: a fatty acid chain that binds reversibly to albumin, a blood protein, so the body clears the molecule slowly. In practice the two half-lives are close enough that both reach steady levels only after several weeks of weekly dosing and take several weeks to wash out after the last dose, which is part of why trials raise the dose gradually rather than starting high.

Which should someone consider, retatrutide or semaglutide?

There is no single right answer, and this is educational context, not a recommendation. The trade-off is larger reported weight change and an extra mechanism (retatrutide) versus a deeper, approved evidence base with hard cardiovascular outcome data (semaglutide).

Semaglutide is the compound with FDA approval for weight management, a long published record, and a dedicated cardiovascular outcome trial behind it, so it is the more anchored, better-documented option today. Retatrutide reported the larger mean weight change of the two, but that figure is from a smaller, shorter phase 2 trial, it has no approval, no hard-outcome data yet, and outside a clinical trial it is not a legally available medicine. If the question is really about the approved GIP plus GLP-1 middle option, that is tirzepatide, covered on the retatrutide vs tirzepatide and semaglutide vs tirzepatide pages. Any decision about these compounds belongs to a qualified clinician, not a web page, and product purity matters for any research compound, which is why a certificate of analysis is worth reviewing (/coa).